The short version of Beta isomer fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-09 and is reviewed periodically as new material appears.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C11H15N2O8P | Identifies the atoms in the nucleotide |
| Molar mass | 334.22 g/mol | Calculated from the molecular formula |
| Appearance | White to off-white powder | Typical for purified solid material |
| Solubility | Water-soluble | Polar nucleotide; less soluble in nonpolar solvents |
| Common synonyms | Nicotinamide mononucleotide; beta-NMN | beta-NMN refers to the common anomeric form |
Research on NMN includes cell studies, animal experiments, and a growing number of human trials. Many early findings come from mice, where changes in NAD+ levels and metabolic markers have been reported. Human data are more limited, and questions remain about effective routes of administration, tissue distribution, and long-term effects. Some trials measure NAD+ in blood or tissue, while others assess physical function or metabolic outcomes. Regulatory status differs between countries, and NMN is not universally approved as a dietary supplement or therapeutic agent.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.
The term NMN commonly refers to the beta isomer, in which the nicotinamide group is attached to the ribose through a beta-glycosidic bond. Commercial material may be supplied as the free acid or as a salt, such as a sodium salt, which affects molecular weight and water solubility. Related compounds include nicotinamide riboside and NAD+ itself, but these are distinct molecules with different formulas and cellular handling. Laboratory research often uses the beta form because it matches the naturally occurring configuration found in biological systems.
Small amounts of NMN occur in some foods, including certain vegetables, fruits, and animal products, though the quantities are generally low and variable. Human cells also synthesize NMN internally from nicotinamide and other precursors. Research interest increased after studies examined whether raising NAD+ levels affects metabolism and aging-related pathways in animals. Evidence in humans remains limited and mixed for many outcomes, and questions about effective absorption, tissue delivery, and long-term effects are still open. Regulatory status differs by country, with some markets treating NMN as a supplement ingredient and others restricting its sale.
The central pathways of metabolism described above, such as glycolysis and the citric acid cycle, are present in all three domains of living things and were present in the last universal common ancestor. This universal ancestral cell was prokaryotic and probably a methanogen that had extensive amino acid, nucleotide, carbohydrate and lipid metabolism. The retention of these ancient pathways during later evolution may be the result of these reactions having been an optimal solution to their particular metabolic problems, with pathways such as glycolysis and the citric acid cycle producing their end products highly efficiently and in a minimal number of steps. The first pathways of enzyme-based metabolism may have been parts of purine nucleotide metabolism, while previous metabolic pathways were a part of the ancient RNA world. Many models have been proposed to describe the mechanisms by which novel metabolic pathways evolve. These include the sequential addition of novel enzymes to a short ancestral pathway, the duplication and then divergence of entire pathways as well as the recruitment of pre-existing enzymes and their assembly into a novel reaction pathway. The relative importance of these mechanisms is unclear, but genomic studies have shown that enzymes in a pathway are likely to have a shared ancestry, suggesting that many pathways have evolved in a step-by-step fashion with novel functions created from pre-existing steps in the pathway.
The direct gating or opening of the chloride ion channel is the reason for the increased toxicity of barbiturates compared to benzodiazepines in overdose. Further, barbiturates are relatively non-selective compounds that bind to an entire superfamily of ligand-gated ion channels, of which the GABAA receptor channel is only one of several representatives. This Cys-loop receptor superfamily of ion channels includes the neuronal nACh receptor channel, the 5-HT3 receptor channel, and the glycine receptor channel. However, while GABAA receptor currents are increased by barbiturates (and other general anesthetics), ligand-gated ion channels that are predominantly permeable for cationic ions are blocked by these compounds. For example, neuronal nAChR channels are blocked by clinically relevant anesthetic concentrations of both thiopental and pentobarbital. Such findings implicate (non-GABA-ergic) ligand-gated ion channels, e.g. the neuronal nAChR channel, in mediating some of the (side) effects of barbiturates. This is the mechanism responsible for the (mild to moderate) anesthetic effect of barbiturates in high doses when used in anesthetic concentration.
Metreleptin, sold under the brand name Myalept among others, is a synthetic analog of the hormone leptin used to treat various forms of dyslipidemia. It has been approved in Japan for metabolic disorders including lipodystrophy and in the United States as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy. The most common side effects include hypoglycemia and weight loss. It was approved for medical use in Canada in January 2024.
==== Decapods ==== If lobsters are injected with serotonin, they behave like dominant individuals whereas octopamine causes subordinate behavior. A crayfish that is frightened may flip its tail to flee, and the effect of serotonin on this behavior depends largely on the animal's social status. Serotonin inhibits the fleeing reaction in subordinates, but enhances it in socially dominant or isolated individuals. The reason for this is social experience alters the proportion between serotonin receptors (5-HT receptors) that have opposing effects on the fight-or-flight response. The effect of 5-HT1 receptors predominates in subordinate animals, while 5-HT2 receptors predominates in dominants.
Sources: en.wikipedia.org
Eukaryotic translation initiation factor 4E, also known as eIF4E, is a protein in humans encoded by the EIF4E gene. eIF4E plays a central role in translation initiation and is involved in regulating protein synthesis. Its mRNA cap-binding activity influences a range of biological processes and disease states, making it an important target for therapeutic development, particularly in disorders characterized by aberrant protein production.
== Research and publications == Kalra has emphasised the importance of person-centred care for over a decade through his reviews, research, and communications in various national and international journals. One of his earlier citations on this topic dates back to a paper he led in 2013, in which he described the role of a person-centred approach during insulin initiation and intensification—one of the most challenging aspects of diabetes management.79 Although a substantial body of his work has focused on diabetes,77,79 he has also applied the principles of person-centred care to other chronic metabolic disorders, including obesity, hypogonadism, and hypothyroidism.78 Kalra has written on menopause distress and late-onset male hypogonadism, simplifying their definitions and describing person-centric thresholds, targets, tools, and techniques for management.167,168 He is also the lead author of a paper titled Thyroid Tantrums in Teenagers, which highlights the variability in endocrine presentations during adolescence and addresses management, assessment, testing techniques, associated biomedical illness, and training. His work extends across all age groups; for instance, he has published geriatric goalposts on independence and interdependence, emphasising the importance of person-centric care in older adults. Key principles of person-centred care highlighted in Kalra's publications include effective communication with patients.65,102 Other core principles include ensuring that therapy is affordable and that the management plan is feasible for the patient.
=== Direct algicidal mechanisms === Direct algicidal mechanisms include methods in which bacterial cells physically interact with algal cells. For example, Streptomyces globisporus strain G9 utilizes hyphae to entrap Microcystis aeruginosa, shading the phytoplankton from sunlight, causing photoinhibition. Another example is compound production triggered by direct cell contact. For instance, Chitinimonas prasina strain LY03 attaches to diatoms that contain chitin in their cell walls directed by their bacterial flagellum, and then produce chitinases that cause diatom lysis. In some instances, locally concentrated compounds have to reach specific levels in order to become algicidal.
=== Gm–Gu === Leopold Gmelin (1788–1853), German chemist who discovered potassium ferricyanide; author of Handbook of Chemistry, which is still used Theodore Nicolas Gobley (1811–1874), French chemist, pioneer in brain tissues analysis, discoverer of lecithin Sulamith Goldhaber (1923–1965), Austrian-American chemist, high-energy physicist, and molecular spectroscopist Victor Goldschmidt (1888–1947), Norwegian mineralogist considered to be one of the founders of modern geochemistry Moses Gomberg (1866–1947), Russian-American chemist, known for pioneering work in radical chemistry Mary L. Good (1931–2019), American inorganic chemist who studied catalysis by ruthenium David van Goorle also called Gorlaeus (1591–1612), Dutch chemist, one of the first modern atomists, who thought that all bodies are made up of atoms Loney Gordon (1915–1999), American chemist who assisted in creating the pertussis vaccine Carl Gräbe (1841–1927), German chemist who synthesized the dye alizarin Thomas Graham (1805–1869), Scottish chemist known for pioneering work on dialysis and diffusion of gases Harry B. Gray (born 1935), American chemist known for the kinetics of long-range electron-transfer reactions in metalloproteins; 2004 Wolf Prize in Chemistry Martha Greenblatt (born 1941), American solid state inorganic chemist, 2003 American Chemical Society's Garvan-Olin Medal Bettye Washington Greene (1935–1995), American industrial chemist who studied colloid and latex chemistry, including interactions between latex and paper Sandra C.
== Epidemiology == Globally, the prevalence and incidence of pulmonary fibrosis has been studied in the United States, Norway, Czech Republic, Greece, United Kingdom, Finland, and Turkey, with only two studies in Japan and Taiwan. But most of these studies were of people already diagnosed with pulmonary fibrosis, which lowers the diagnosis sensitivity, so that the prevalence and incidence has ranged from 0.7 per 100,000 in Taiwan to 63.0 per 100,000 in the U.S., and the published incidence has ranged from 0.6 per 100,000 person years to 17.4 per 100,000 person years. The mean age of all pulmonary fibrosis patients is between 65 and 70 years, making age a criterion of its own. Aging respiratory systems are much more vulnerable to fibrosis and stem cell depletion.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a nucleotide intermediate in the cellular pathway that produces NAD+, a coenzyme involved in energy metabolism and signaling. NMN is not the same compound as NAD+.
NMN is a direct precursor to NAD+ in the salvage pathway. The enzyme NMNAT converts NMN into NAD+ by adding an adenine nucleotide group. This relationship is why NMN is studied in the context of NAD+ decline.
Yes, NMN is produced naturally in cells as part of NAD+ recycling. It also appears in small and variable amounts in some foods. Its natural presence does not by itself establish that supplemental NMN has clinical benefits.
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis.